These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 17785545)

  • 21. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer.
    Gellert GC; Dikmen ZG; Wright WE; Gryaznov S; Shay JW
    Breast Cancer Res Treat; 2006 Mar; 96(1):73-81. PubMed ID: 16319992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telomerase as a target for cancer therapy.
    Parkinson KE
    Curr Opin Investig Drugs; 2005 Jun; 6(6):605-10. PubMed ID: 15988912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced or diminished stabilization of the telomere G-quadruplex and inhibition of telomerase by small chemical ligands under molecular crowding condition.
    Chen Z; Zheng KW; Hao YH; Tan Z
    J Am Chem Soc; 2009 Aug; 131(30):10430-8. PubMed ID: 19588966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telomere lengthening in telomerase-negative cells: the ends are coming together.
    Scheel C; Poremba C
    Virchows Arch; 2002 Jun; 440(6):573-82. PubMed ID: 12070595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines.
    Zhou JM; Zhu XF; Lu YJ; Deng R; Huang ZS; Mei YP; Wang Y; Huang WL; Liu ZC; Gu LQ; Zeng YX
    Oncogene; 2006 Jan; 25(4):503-11. PubMed ID: 16170347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting telomerase and telomeres: a click chemistry approach towards highly selective G-quadruplex ligands.
    Moorhouse AD; Haider S; Gunaratnam M; Munnur D; Neidle S; Moses JE
    Mol Biosyst; 2008 Jun; 4(6):629-42. PubMed ID: 18493662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies.
    Keith WN; Bilsland A; Hardie M; Evans TR
    Nat Clin Pract Oncol; 2004 Dec; 1(2):88-96. PubMed ID: 16264826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting telomerase and telomeres to enhance ionizing radiation effects in in vitro and in vivo cancer models.
    Berardinelli F; Coluzzi E; Sgura A; Antoccia A
    Mutat Res Rev Mutat Res; 2017 Jul; 773():204-219. PubMed ID: 28927529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition.
    Castelo-Branco P; Zhang C; Lipman T; Fujitani M; Hansford L; Clarke I; Harley CB; Tressler R; Malkin D; Walker E; Kaplan DR; Dirks P; Tabori U
    Clin Cancer Res; 2011 Jan; 17(1):111-21. PubMed ID: 21208905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532).
    El Daly H; Martens UM
    Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telomeres, telomerase, and apoptosis.
    Mondello C; Scovassi AI
    Biochem Cell Biol; 2004 Aug; 82(4):498-507. PubMed ID: 15284903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells.
    Phatak P; Dai F; Butler M; Nandakumar MP; Gutierrez PL; Edelman MJ; Hendriks H; Burger AM
    Clin Cancer Res; 2008 Jul; 14(14):4593-602. PubMed ID: 18628474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The telomeric PARP, tankyrases, as targets for cancer therapy.
    Seimiya H
    Br J Cancer; 2006 Feb; 94(3):341-5. PubMed ID: 16421589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telomere dysfunction and telomerase activation in cancer--a pathological paradox?
    Calcagnile O; Gisselsson D
    Cytogenet Genome Res; 2007; 118(2-4):270-6. PubMed ID: 18000380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trisubstituted acridines as G-quadruplex telomere targeting agents. Effects of extensions of the 3,6- and 9-side chains on quadruplex binding, telomerase activity, and cell proliferation.
    Moore MJ; Schultes CM; Cuesta J; Cuenca F; Gunaratnam M; Tanious FA; Wilson WD; Neidle S
    J Med Chem; 2006 Jan; 49(2):582-99. PubMed ID: 16420044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telomerase and cancer.
    Testorelli C
    J Exp Clin Cancer Res; 2003 Jun; 22(2):165-9. PubMed ID: 12866565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telomeres and telomerase: Biological and clinical importance in dogs.
    Nasir L
    Vet J; 2008 Feb; 175(2):155-63. PubMed ID: 17398127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins.
    Potts PR; Yu H
    Nat Struct Mol Biol; 2007 Jul; 14(7):581-90. PubMed ID: 17589526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of telomerase in cancer.
    Kim NW
    Eur J Cancer; 1997 Apr; 33(5):781-6. PubMed ID: 9282117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Telomere and telomerase as targets for anti-cancer drugs].
    Ide T
    Nihon Rinsho; 2004 Jul; 62(7):1271-6. PubMed ID: 15283143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.